Increased expression of the proto-oncogene, c-myc, in human neuroblastoma cells by reversible inhibition of cell growth

Anticancer Res. 1991 Nov-Dec;11(6):1967-73.

Abstract

Expression of the proto-oncogenes N-myc and c-myc in the human neuroblastoma cell line, IMR32, was examined after reversible inhibition of DNA synthesis by treatment with deferoxamine. After 48 h treatment with 10(-5) M deferoxamine, the number of c-myc expressing cells doubled, while N-myc expressing cells did not change. The expression level of c-myc in each cell also increased. These results suggested that the synthesis of cellular factor(s) involved in the degradation of c-myc RNA or its product was suppressed by reversible inhibition of cell growth. The regulatory mechanisms of expression of N-myc and c-myc may be distinct.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Cycle / drug effects
  • DNA, Neoplasm / biosynthesis
  • Deferoxamine / pharmacology*
  • Gene Expression Regulation, Neoplastic / drug effects*
  • Gene Expression Regulation, Neoplastic / genetics
  • Genes, myc*
  • Humans
  • Neuroblastoma / genetics*
  • Neuroblastoma / pathology
  • Proto-Oncogene Mas
  • Tumor Cells, Cultured

Substances

  • DNA, Neoplasm
  • MAS1 protein, human
  • Proto-Oncogene Mas
  • Deferoxamine